Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nationwide USIC 2000 registry
暂无分享,去创建一个
N. Danchin | D. Blanchard | P. Guéret | L. Vaur | N. Genès | P. Clerson | J. Lablanche | J. Cambou | G. Hanania | Y. Boutalbi | N. Danchin | R. Humbert | P. Guéret
[1] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[2] Hugo A. Katus,et al. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, European heart journal.
[3] P. Sritara,et al. Reduced in-hospital mortality from acute myocardial infarction with general adoption of thrombolytic treatment in the North West Thames health region 1979-1991. , 1995, British heart journal.
[4] J. Gore,et al. Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective. , 2001, Journal of the American College of Cardiology.
[5] H. Dauerman,et al. Ten-year trends in the incidence, treatment, and outcome of Q-wave myocardial infarction. , 2000, The American journal of cardiology.
[6] P. Kudenchuk,et al. Hospital mortality in acute myocardial infarction in the era of reperfusion therapy (the Myocardial Infarction Triage and Intervention Project). , 1993, The American journal of cardiology.
[7] M L Simoons,et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). , 2002, European heart journal.
[8] HOMAS,et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .
[9] Johan Herlitz,et al. Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .
[10] Javed Butler,et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. , 2002, Journal of the American College of Cardiology.
[11] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[12] D. Arveiler,et al. Prise en charge thérapeutique de l'infarctus du myocarde : évolution dans le projet MONICA-France entre 1985 et 1991 , 1996 .
[13] G. Lamas,et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.
[14] Adam Brown,et al. Demographic, belief, and situational factors influencing the decision to utilize emergency medical services among chest pain patients. Rapid Early Action for Coronary Treatment (REACT) study. , 2000, Circulation.
[15] Raymond C. Schneider,et al. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.
[16] B. Modan,et al. Twenty-five-year mortality rate decrease in patients in Israel with a first episode of acute myocardial infarction. Secondary Prevention Reinfarction Israeli Nifedipine Trial Study Group. Israeli Thrombolytic Survey Group. , 1995, American heart journal.
[17] J S Alpert,et al. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.
[18] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[19] P. Marques-Vidal,et al. Distribution et prise en charge des facteurs de risque cardiovasculaires chez des patients coronariens : étude Prévenir , 2001 .
[20] H. Krumholz,et al. Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. , 1998, JAMA.
[21] C. Fry,et al. Science of urinary incontinence Report of a Meeting of Physicians and Scientists, University College London , 1994, The Lancet.
[22] J. Stengård,et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.
[23] R. Califf,et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. , 1997 .
[24] Richard P. Lewis,et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.
[25] J. Ferrières,et al. Effect of reperfusion therapy on long-term outcome in patients >70 years of age. , 2002, The American journal of cardiology.
[26] E. Antman,et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.
[27] K. Swedberg,et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) , 1992, The New England journal of medicine.
[28] J. Leor,et al. Sex Differences in Management and Outcome After Acute Myocardial Infarction in the 1990s: A Prospective Observational Community-Based Study , 2000, Circulation.
[29] W. Rogers,et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. , 2000, Journal of the American College of Cardiology.
[30] J. Berning,et al. Early estimation of risk by echocardiographic determination of wall motion index in an unselected population with acute myocardial infarction. , 1990, The American journal of cardiology.
[31] C. Alauze,et al. Intérêt d’une campagne d’information régionale sur les urgences cardiaques et l’appel au 15 , 2003 .
[32] Frans Van de Werf,et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. , 2003 .
[33] J. Ferrières,et al. Management of acute myocardial infarction in intensive care units in 1995: a nationwide French survey of practice and early hospital results. , 1997, Journal of the American College of Cardiology.
[34] Fibrinolytic Therapy Trialists' Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994, The Lancet.
[35] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[36] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[37] H. White. Thrombolytic therapy in the elderly , 2000, The Lancet.
[38] N. Dudley. Thrombolytic therapy in the elderly. , 1991, Postgraduate medical journal.
[39] Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.. GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction , 1994, The Lancet.
[40] B. Modan,et al. Twenty-five—year mortality rate decrease in patients in Israel with a first episode of acute myocardial infarction , 1995 .
[41] D. Baim,et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. , 1999, The New England journal of medicine.
[42] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[43] J. Ferrières,et al. Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey , 2002, Heart.
[44] R. Califf,et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.
[45] L. Goldman,et al. Impact of a public campaign on pre-hospital delay in patients reporting chest pain. , 1996, Heart.
[46] D. Arveiler,et al. [Evaluation of the status of access to emergency care of subjects with myocardial infarction]. , 1988, Revue d'epidemiologie et de sante publique.
[47] T. Heer,et al. Gender differences in acute myocardial infarction in the era of reperfusion (the MITRA registry). , 2002, The American journal of cardiology.